Pharmaceuticals North America

North America Insulin Biosimilars Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

North America Insulin Biosimilars Market Industry Trends and Forecast to 2034: Segmented by (Type, Delivery, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

North America · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $1.98 Bn Placeholder estimate
Estimate 2025 $2.25 Bn 50.8% of the global market
Projected 2034 $6.85 Bn 205.2% Adds $4.61 Bn over 9 forecast years
CAGR 2025–2034 13.2% Faster than 74% of 180 Pharmaceuticals markets here
Key players 6 +1
  • North America is 50.82% of the global market.
  • Among regions, the largest is North America (this report) at $2.25 Bn.
  • Fastest growing: Africa at 15.3% a year.
  • North America ranks 1st of 6 by size among regions.

Market size projection

North America

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$4.61 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Insulin Biosimilars Market market size by year, North America
YearMarket sizeChange that yearSince 2025
2024 (estimate) $1.98 Bn — —
2025 (base) $2.25 Bn +$261.9 Mn —
2026 (forecast) $2.54 Bn +$296.4 Mn +13.2%
2027 (forecast) $2.88 Bn +$335.6 Mn +28.1%
2028 (forecast) $3.26 Bn +$379.9 Mn +45.1%
2029 (forecast) $3.69 Bn +$430.0 Mn +64.2%
2030 (forecast) $4.17 Bn +$486.8 Mn +85.9%
2031 (forecast) $4.73 Bn +$551.0 Mn +110.4%
2032 (forecast) $5.35 Bn +$623.7 Mn +138.2%
2033 (forecast) $6.06 Bn +$706.1 Mn +169.6%
2034 (forecast) $6.85 Bn +$799.3 Mn +205.2%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

North America Insulin Biosimilars Market Analysis at a glance
Market size, 2025$2.25 Bn placeholder estimate
Forecast, 2034$6.85 Bn placeholder estimate
Growth (CAGR), 2025–203413.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, delivery and end user (see all)
Key playersBiocon, Viatris, Sanofi, Eli Lilly and Company, Gan & Lee Pharmaceuticals and 1 more (see all)
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The North America Insulin Biosimilars Market Analysis Executive Summary

Insulin biosimilars are lower-cost versions of branded insulins that work the same way, improving access to diabetes treatment.

Key segments of the insulin Biosimilars market include type (Long-Acting, Rapid-Acting and Premixed) and delivery (Vials, Pens and Cartridges).

Bar chart: North America Insulin Biosimilars market size, 2024–2034, placeholder estimates. $1.98 Bn in 2024, $2.25 Bn in 2025 and $6.85 Bn in 2034, 13.2% CAGR.
North America Insulin Biosimilars market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

North America Insulin Biosimilars Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the insulin Biosimilars market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the insulin Biosimilars market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the insulin Biosimilars market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Insulin Biosimilars Market in North America

The insulin Biosimilars market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Insulin Biosimilars Market in North America

Insulin Biosimilars in North America: rules and payment

In the countries we cover here, medicines are approved by Health Canada (Canada)⁠[1] and FDA (US)⁠[2]. How care is paid for in these countries: provincial health insurance (Canada)⁠[3] and Medicare and Medicaid (US)⁠[4].

[1] Health Canada. Checked 14 Nov 2026.

[2] US Food and Drug Administration. Checked 14 Nov 2026.

[3] Health Canada. Checked 14 Nov 2026.

[4] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for insulin Biosimilars. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in North America.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Insulin Biosimilars right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Insulin Biosimilars in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Insulin Biosimilars market in North America?
Placeholder estimate: about $2.25 Bn in 2025, rising to about $6.85 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Insulin Biosimilars market in North America growing?
Placeholder estimate: about 13.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Insulin Biosimilars market report cover?
The report splits the market by type (Long-Acting, Rapid-Acting, Premixed), delivery (Vials, Pens, Cartridges) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Insulin Biosimilars market?
Key players include Biocon, Viatris, Sanofi, Eli Lilly and Company, Gan & Lee Pharmaceuticals and Wockhardt Ltd..
What is driving the Insulin Biosimilars market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the insulin Biosimilars market.
How much research is published on Insulin Biosimilars?
PubMed lists 35 papers on Insulin Biosimilars added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in North America

See all

Related on diabetes and biologics and biosimilars

See the topic